BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Study or Subgroup	Sacubitril/valsartan Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
2.4.1 All HFrEF patients						
AWAKE-HF 2019	5	69	4	70	0.2%	1.27 [0.36, 4.52]
CLCZ696B2223	0	8	0	8		Not estimable
EVALUTE-HF 2019	1	231	1	232	0.0%	1.00 [0.06, 15.96]
Subtotal (95% CI)		**308**		**310**	**0.2%**	**1.22 [0.38, 3.86]**
Total events	6		5			
Heterogeneity: Chi² = 0.02, df = 1 (P = 0.88); I² = 0%						
Test for overall effect: Z = 0.33 (P = 0.74)						
2.4.2 Guideline recommended						
Li J 2019 (1)	3	62	5	64	0.2%	0.62 [0.15, 2.48]
OUTSTEP-HF	19	309	28	310	1.3%	0.68 [0.39, 1.19]
PARADIGM-HF 2014	1937	4203	2142	4229	97.8%	0.91 [0.87, 0.95]
PRIME-HF 2019	7	60	9	58	0.4%	0.75 [0.30, 1.89]
Subtotal (95% CI)		**4634**		**4661**	**99.8%**	**0.91 [0.87, 0.95]**
Total events	1966		2184			
Heterogeneity: Chi² = 1.48, df = 3 (P = 0.69); I² = 0%						
Test for overall effect: Z = 4.40 (P < 0.0001)						
Total (95% CI)		**4942**		**4971**	**100.0%**	**0.91 [0.87, 0.95]**
Total events	1972		2189			
Heterogeneity: Chi² = 1.75, df = 5 (P = 0.88); I² = 0%						
Test for overall effect: Z = 4.37 (P < 0.0001)						
Test for subgroup differences: Chi² = 0.25, df = 1 (P = 0.62), I² = 0%